

Jonathan D Tward

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1324290/publications.pdf>

Version: 2024-02-01

101
papers

4,548
citations

185998

28
h-index

102304

66
g-index

104
all docs

104
docs citations

104
times ranked

6919
citing authors

#	ARTICLE	IF	CITATIONS
1	Cancer Misinformation and Harmful Information on Facebook and Other Social Media: A Brief Report. <i>Journal of the National Cancer Institute</i> , 2022, 114, 1036-1039.	3.0	74
2	Interplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Prostate Cancer. <i>JAMA Oncology</i> , 2022, 8, e216871.	3.4	18
3	Nomograms for metastasis-free and overall survival for pathologically node positive prostate cancer patients treated with or without radiation therapy plus short-term ADT. <i>Clinical Genitourinary Cancer</i> , 2022, , .	0.9	1
4	The Clinical Significance of Maximum Tumor Diameter on MRI in Men Undergoing Radical Prostatectomy or Definitive Radiotherapy for Locoregional Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2022, 20, e453-e459.	0.9	2
5	A Systematic Review of the Evidence for the Decipher Genomic Classifier in Prostate Cancer. <i>European Urology</i> , 2021, 79, 374-383.	0.9	93
6	Rare Genitourinary Malignancies (Penile, Urethral, Renal Pelvis, and Ureteral Cancers). <i>Practical Guides in Radiation Oncology</i> , 2021, , 313-362.	0.0	0
7	Patterns of Care and Treatment Outcomes in Locoregional Squamous Cell Carcinoma of the Prostate. <i>European Urology Open Science</i> , 2021, 23, 30-33.	0.2	3
8	Clinical Germline Testing Results of Men With Prostate Cancer: Patient-Level Factors and Implications of NCCN Guideline Expansion. <i>JCO Precision Oncology</i> , 2021, 5, 533-542.	1.5	6
9	Temporal Trends and Predictors in Diagnosing Pathologic Node-Positive Prostate Cancer in Clinically Node-Negative Patients. <i>Clinical Genitourinary Cancer</i> , 2021, , .	0.9	1
10	Comparison of Multimodal Therapies and Outcomes Among Patients With High-Risk Prostate Cancer With Adverse Clinicopathologic Features. <i>JAMA Network Open</i> , 2021, 4, e2115312.	2.8	12
11	The Stage at Presentation and Oncologic Outcomes for Agent Orange Exposed and Non-Exposed United States Veterans Diagnosed With Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 369-369.e7.	0.9	1
12	Patterns of Clinical Progression in Radiorecurrent High-risk Prostate Cancer. <i>European Urology</i> , 2021, 80, 142-146.	0.9	12
13	Personalizing Localized Prostate Cancer: Validation of a Combined Clinical Cell-cycle Risk (CCR) Score Threshold for Prognosticating Benefit From Multimodality Therapy. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 296-304.e3.	0.9	6
14	Stage Presentation, Care Patterns, Treatment Outcomes, and Impact of Radiotherapy on Overall Survival for Adrenocortical Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 417-424.	0.9	4
15	The clinical cell-cycle risk (CCR) score is associated with metastasis after radiation therapy and provides guidance on when to forgo combined androgen deprivation therapy with dose-escalated radiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, , .	0.4	9
16	Performance of a Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomographyâ€Derived Risk-Stratification Tool for High-risk and Very High-risk Prostate Cancer. <i>JAMA Network Open</i> , 2021, 4, e2138550.	2.8	18
17	Analysis of the prognostic utility of the cell cycle progression (CCP) score generated from needle biopsy in men treated with definitive therapy. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 102-107.	2.0	26
18	Absolute versus Relative Benefit of Androgen Deprivation Therapy for Prostate Cancer: Moving Beyond the Hazard Ratio to Personalize Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 899-902.	0.4	7

#	ARTICLE	IF	CITATIONS
19	Comparison of transperineal ultrasound image guidance technique to transabdominal technique for prostate radiation therapy. <i>Medical Physics</i> , 2020, 47, 6113-6121.	1.6	2
20	Impact and Outcomes of Pretreatment Total Serum Testosterone on Localized Prostate Cancer Patients. <i>Prostate Cancer</i> , 2020, 2020, 1-9.	0.4	1
21	Metastasis, Mortality, and Quality of Life for Men With NCCN High and Very High Risk Localized Prostate Cancer After Surgical and/or Combined Modality Radiotherapy. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 274-283.e5.	0.9	11
22	Definitive Chemoradiotherapy for Locally Advanced, Lymph-node Positive, Nonmetastatic Penile Squamous Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e573-e584.	0.9	6
23	MP37-20â€fPATIENT-LEVEL FACTORS ARE NOT ASSOCIATED WITH IMPROVED IDENTIFICATION OF GERMLINE PATHOGENIC VARIANTS IN MEN WITH PROSTATE CANCER. <i>Journal of Urology</i> , 2020, 203, .	0.2	0
24	Germline Variants in Highly Selected Patients With Prostate Cancer. <i>JAMA Oncology</i> , 2019, 5, 1368.	3.4	1
25	Calculation of delivered composite dose from Calypso tracking data for prostate cancer: And subsequent evaluation of reasonable treatment interruption tolerance limits. <i>Journal of Applied Clinical Medical Physics</i> , 2019, 20, 105-113.	0.8	1
26	Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 479-505.	2.3	943
27	MP41-06â€fGERMLINE GENETIC TESTING IN MEN WITH PROSTATE CANCER: CLINICAL CHARACTERISTICS AND TESTING OUTCOMES IN A NEWLY INDICATED POPULATION. <i>Journal of Urology</i> , 2019, 201, .	0.2	0
28	Identification of men with low-risk biopsy-confirmed prostate cancer as candidates for active surveillance. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 310.e7-310.e13.	0.8	19
29	Patterns of care and outcomes in gliosarcoma: an analysis of the National Cancer Database. <i>Journal of Neurosurgery</i> , 2018, 128, 1133-1138.	0.9	37
30	Daily breathing inconsistency in pancreas SBRT: a 4DCT study. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 989-995.	0.6	1
31	Demographics, stage distribution, and relative roles of surgery and radiotherapy on survival of persons with primary prostate sarcomas. <i>Cancer Medicine</i> , 2018, 7, 6030-6039.	1.3	5
32	NCCN Guidelines Insights: Bladder Cancer, Version 5.2018. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 1041-1053.	2.3	171
33	The case for nonsurgical therapy of nonmetastatic penile cancer. <i>Nature Reviews Urology</i> , 2018, 15, 574-584.	1.9	16
34	Factors influencing prostate cancer patterns of care: An analysis of treatment variation using the SEER database. <i>Advances in Radiation Oncology</i> , 2018, 3, 170-180.	0.6	47
35	Impact of prone versus supine positioning on small bowel dose with pelvic intensity modulated radiation therapy. <i>Advances in Radiation Oncology</i> , 2017, 2, 235-243.	0.6	9
36	Orgasmic Function after Radical Prostatectomy. <i>Journal of Urology</i> , 2017, 198, 407-413.	0.2	8

#	ARTICLE	IF	CITATIONS
37	Urinary Diversion for Severe Urinary Adverse Events of Prostate Radiation: Results from a Multi-Institutional Study. <i>Journal of Urology</i> , 2017, 197, 744-750.	0.2	23
38	Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 1240-1267.	2.3	220
39	Comparison of treatment modalities for breast cancer arising in Hodgkin's lymphoma survivors. <i>Journal of Radiation Oncology</i> , 2017, 6, 65-72.	0.7	3
40	Management of Radiation Therapy Oncology Group grade 4 urinary adverse events after radiotherapy for prostate cancer. <i>BJU International</i> , 2017, 119, 700-708.	1.3	13
41	Comparison of 2 transabdominal ultrasound image guidance techniques for prostate and prostatic fossa radiation therapy. <i>Practical Radiation Oncology</i> , 2017, 7, e99-e107.	1.1	2
42	Risk of Death from Prostate Cancer with and without Definitive Local Therapy when Gleason Pattern 5 is Present: A Surveillance, Epidemiology, and End Results Analysis. <i>Cureus</i> , 2017, 9, e1453.	0.2	4
43	NCCN Guidelines Insights: Bladder Cancer, Version 2.2016. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 1213-1224.	2.3	93
44	MP14-14 MANAGEMENT OF RADIATION THERAPY ONCOLOGY GROUP (RTOG) GRADE 4 UROLOGIC COMPLICATIONS OF RADIOTHERAPY FOR PROSTATE CANCER. <i>Journal of Urology</i> , 2016, 195, .	0.2	0
45	Surgical Management of Ureteral Strictures Arising From Radiotherapy for Prostate Cancer. <i>Urology Case Reports</i> , 2016, 6, 47-49.	0.1	9
46	Time Course and Accumulated Risk of Severe Urinary Adverse Events After High- Versus Low-Dose-Rate Prostate Brachytherapy With or Without External Beam Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 95, 1443-1453.	0.4	24
47	MP80-03 ORGASMIC FUNCTION AFTER RADICAL PROSTATECTOMY. <i>Journal of Urology</i> , 2016, 195, .	0.2	0
48	Risk of Death from Prostate Cancer with and without Definitive Local Therapy When Primary or Secondary Gleason Pattern 5 Is Present: A Seer Analysis. <i>Brachytherapy</i> , 2016, 15, S202-S203.	0.2	0
49	PD12-06 URINARY DIVERSION FOR COMPLICATIONS OF RADIATION THERAPY FOR THE TREATMENT OF PROSTATE CANCER: UPDATED RESULTS FROM THE TRAUMA AND UROLOGIC RESEARCH NETWORK OF SURGEONS. <i>Journal of Urology</i> , 2016, 195, .	0.2	0
50	Durable Response to Treatment With Combination Radiotherapy and High-dose Interleukin-2 in Metastatic Chromophobe Variant Renal Cell Carcinoma. <i>Journal of Immunotherapy</i> , 2016, 39, 101-103.	1.2	2
51	Long-term comparative toxicity of LDR versus HDR prostate brachytherapy ± EBRT and evaluation of risk hazard over time: A SEER-Medicare analysis.. <i>Journal of Clinical Oncology</i> , 2016, 34, 108-108.	0.8	1
52	Current and Emerging Modalities. , 2016, , 183-199.		0
53	Reduction in therapeutic burden from use of CCP test in treatment decisions among newly diagnosed prostate cancer patients independent of Charlson Comorbidity Index.. <i>Journal of Clinical Oncology</i> , 2016, 34, e16572-e16572.	0.8	0
54	Stereotactic Body Radiotherapy for Hepatocellular Carcinoma Resulting in a Durable Relapse-Free Survival: A Case Report. <i>Cureus</i> , 2016, 8, e841.	0.2	0

#	ARTICLE	IF	CITATIONS
55	PD11-02 URINARY DIVERSION FOR COMPLICATIONS OF PROSTATE CANCER RADIATION TREATMENT. Journal of Urology, 2015, 193, .	0.2	0
56	Palladium interstitial implant in combination with external beam radiotherapy and chemotherapy for the definitive treatment of a female urethral carcinoma. Gynecologic Oncology Reports, 2015, 13, 40-43.	0.3	2
57	Local control after stereotactic radiosurgery for brain metastases in patients with melanoma with and without BRAF mutation and treatment. Journal of Neurosurgery, 2015, 123, 395-401.	0.9	64
58	Grade 3 or higher morbidity requiring urologic surgical management following curative-intent radiotherapy of localized prostate cancer: Patient characteristics.. Journal of Clinical Oncology, 2015, 33, 116-116.	0.8	1
59	Definitive treatment of localized prostate cancer: Time and geographic trends.. Journal of Clinical Oncology, 2015, 33, 132-132.	0.8	1
60	Prostate patterns of care.. Journal of Clinical Oncology, 2015, 33, 117-117.	0.8	0
61	Adjuvant radiotherapy after prostatectomy: have randomized clinical trials had any impact?. Journal of Radiation Oncology, 2014, 3, 387-394.	0.7	3
62	Stage Presentation, Care Patterns, and Treatment Outcomes for Squamous Cell Carcinoma of the Penis. International Journal of Radiation Oncology Biology Physics, 2014, 88, 94-100.	0.4	66
63	Sustained remission of Parkinson disease associated melanoma with immunotherapy. Parkinsonism and Related Disorders, 2014, 20, 1027-1029.	1.1	1
64	Climacturia after Definitive Treatment of Prostate Cancer. Journal of Urology, 2014, 191, 159-163.	0.2	48
65	Prostate Cancer, Version 2.2014. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 686-718.	2.3	294
66	Patterns of Care With Brachytherapy for Cervical Cancer. International Journal of Gynecological Cancer, 2014, 24, 1659-1664.	1.2	22
67	CCP score and risk stratification for prostate cancer patients at biopsy.. Journal of Clinical Oncology, 2014, 32, 47-47.	0.8	4
68	Stereotactic radiosurgery for a single brain metastasis: factors impacting control. Journal of Radiosurgery and SBRT, 2014, 3, 111-121.	0.2	2
69	Radiosurgery for melanoma brain metastases: the impact of hemorrhage on local control. Journal of Radiosurgery and SBRT, 2014, 3, 43-50.	0.2	5
70	Radiation therapy for clinically node-positive prostate adenocarcinoma is correlated with improved overall and prostate cancer-specific survival. Practical Radiation Oncology, 2013, 3, 234-240.	1.1	52
71	Overall Survival Analysis of Adjuvant Radiation Versus Observation in Stage I Testicular Seminoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2013, 36, 500-504.	0.6	22
72	Prostate Cancer, Version 1.2014. Journal of the National Comprehensive Cancer Network: JNCCN, 2013, 11, 1471-1479.	2.3	82

#	ARTICLE	IF	CITATIONS
73	Clinical Versus Pathologic Staging for Prostate Adenocarcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2012, 35, 364-368.	0.6	7
74	Prostate Cancer, Version 3.2012 Featured Updates to the NCCN Guidelines. Journal of the National Comprehensive Cancer Network: JNCCN, 2012, 10, 1081-1087.	2.3	208
75	An evaluation of interference of inflatable penile prostheses with electromagnetic localization and tracking system. Medical Physics, 2012, 39, 4807-4811.	1.6	6
76	Individualized margins for prostate patients using a wireless localization and tracking system. Journal of Applied Clinical Medical Physics, 2011, 12, 194-204.	0.8	5
77	Penile Cancer: Contemporary Considerations in Management of Local Disease. Current Urology, 2011, 5, 62-71.	0.4	3
78	Primary Vaginal Cancer and Chemoradiotherapy: A Patterns-of-Care Analysis. International Journal of Gynecological Cancer, 2011, 21, 378-384.	1.2	26
79	Overall and cause-specific survival for patients undergoing lobectomy, near-total, or total thyroidectomy for differentiated thyroid cancer. Head and Neck, 2011, 33, 645-649.	0.9	183
80	Survival Outcomes in Resected Extrahepatic Cholangiocarcinoma: Effect of Adjuvant Radiotherapy in a Surveillance, Epidemiology, and End Results Analysis. International Journal of Radiation Oncology Biology Physics, 2011, 81, 189-198.	0.4	69
81	American Society for Radiation Oncology (ASTRO) and American College of Radiology (ACR) Practice Guideline for the Performance of High-Dose-Rate Brachytherapy. International Journal of Radiation Oncology Biology Physics, 2011, 79, 641-649.	0.4	43
82	Does Brachytherapy Improve Survival in Addition to External Beam Radiation Therapy in Patients With High Risk Stage I and II Endometrial Carcinoma?. American Journal of Clinical Oncology: Cancer Clinical Trials, 2010, 33, 364-369.	0.6	22
83	Adjuvant Radiotherapy Use and Patterns of Care Analysis for Margin-positive Prostate Adenocarcinoma with Extracapsular Extension: Postprostatectomy Adjuvant Radiotherapy: A SEER Analysis. Urology, 2010, 76, 1169-1174.	0.5	46
84	Relative Contributions of Radiation and Cisplatin-Based Chemotherapy to Sensorineural Hearing Loss in Head-and-Neck Cancer Patients. International Journal of Radiation Oncology Biology Physics, 2009, 73, 779-788.	0.4	97
85	Survival and Recurrence in Nonmycosis Fungoides Primary Cutaneous Lymphoma. Cancer Journal (Sudbury, Mass), 2009, 15, 87-92.	1.0	1
86	Does Radiotherapy or Lymphadenectomy Improve Survival in Endometrial Stromal Sarcoma?. International Journal of Gynecological Cancer, 2009, 19, 1232-1238.	1.2	78
87	The Risk of Second Primary Malignancies up to Three Decades after the Treatment of Differentiated Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 504-515.	1.8	338
88	Adjuvant EBRT improves survival in patients with lymph-node-negative pancreatic cancer. Nature Clinical Practice Oncology, 2008, 5, 438-439.	4.3	0
89	Surgery and Radiotherapy Improves Survival in Patients With Anaplastic Thyroid Carcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2008, 31, 460-464.	0.6	134
90	Incidence, risk factors, and pathogenesis of second malignancies in patients with non-Hodgkin lymphoma. Leukemia and Lymphoma, 2007, 48, 1482-1495.	0.6	12

#	ARTICLE	IF	CITATIONS
91	Brachytherapy monotherapy for older men with prostate cancer. <i>Aging Health</i> , 2007, 3, 653-661.	0.3	0
92	Prostate-Specific Antigen Control with Low-Dose Adjuvant Radiotherapy for High-Risk Prostate Cancer. <i>Urology</i> , 2007, 69, 295-299.	0.5	16
93	Planned Neck Dissection after Definitive Radiotherapy or Chemoradiation for Base of Tongue Cancers. <i>Otolaryngology - Head and Neck Surgery</i> , 2007, 137, 422-427.	1.1	7
94	Descriptive nomograms of adjuvant radiotherapy use and patterns of care analysis for stage I and II endometrial adenocarcinoma: A surveillance, epidemiology, and end results population study. <i>Cancer</i> , 2007, 110, 2092-2100.	2.0	28
95	Radiation therapy is associated with improved survival in patients with pancreatic adenocarcinoma: Results of a study from the surveillance, epidemiology, and end results (SEER) registry data. <i>Cancer</i> , 2007, 110, 2191-2201.	2.0	82
96	The risk of secondary malignancies over 30 years after the treatment of non-Hodgkin lymphoma. <i>Cancer</i> , 2006, 107, 108-115.	2.0	178
97	Malignant phyllodes tumor of the female breast. <i>Cancer</i> , 2006, 107, 2127-2133.	2.0	191
98	Survival of men with clinically localized prostate cancer treated with prostatectomy, brachytherapy, or no definitive treatment. <i>Cancer</i> , 2006, 107, 2392-2400.	2.0	65
99	The Î³-Carboxylation Recognition Site Is Sufficient to Direct Vitamin K-dependent Carboxylation on an Adjacent Glutamate-rich Region of Thrombin in a Propeptide-Thrombin Chimera. <i>Journal of Biological Chemistry</i> , 1997, 272, 28258-28262.	1.6	27
100	Effect of Nicotinamide and Pentoxifylline on Normal Tissue and Tumor Oxygenation. <i>Acta Oncologica</i> , 1995, 34, 391-395.	0.8	10
101	The extent, time course, and fraction size dependence of mouse spinal cord recovery from radiation injury. <i>International Journal of Radiation Oncology Biology Physics</i> , 1994, 30, 609-617.	0.4	25